Appendix cancer historical perspective

Appendix cancer Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Epidemiology and Demographics
Differentiating Appendix cancer from other Diseases
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
MRI
CT scan
Echocardiography and Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Appendix cancer historical perspective On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Appendix cancer historical perspective All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Appendix cancer historical perspective
CDC on Appendix cancer historical perspective
Appendix cancer historical perspective in the news
Blogs on Appendix cancer historical perspective
Directions to Hospitals Treating Appendix cancer
Risk calculators and risk factors for Appendix cancer historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]

Overview

Appendix cancer was first described in the published literature by Sir George Thos. Beatson, an English surgeon, in 1913.Development of surgical sciences revolutionized cancer care, appendix cancer was not an exception. Introduction of chemotherapy agents such as 5-fluorouracil (5-FU) Irinotecan, Oxaliplatin, Vascular endothelial growth factor receptor inhibitors (bevacizumab), Epidermal growth factor receptor inhibitors (cetuximab and panitumumab), Aflibercept, Regorafenib: inhibitor of angiogenic tyrosine kinases (including the VEGF receptors 1,2, and 3), Capecitabine as well as introduction of intraperitoneal chemotherapy including hyperthermic intraperitoneal chemotherapyadvanced appendix cancer treatment. Development of new Imaging modalities such as CT scan, MRI as well as specific imaging modalities such as Somatostatin scintigraphy also transfigured approaching to the patients with appendix cancer. Genetic studies introduced novel horizons in approaching patients with appendix cancer.

Historical Perspective

Discovery

• Appendix cancer was first described in the published literature by Sir George Thos. Beatson, an English surgeon, in 1913.

Landmark Events in the Development of Treatment Strategies

• Surgical sciences development

• Appendectomy
• Anesthesia
• Sterilization
• Laparoscopy

• Chemotherapy

• Introduction of 5-fluorouracil (5-FU) the first coorectal chemotherapy agent
• Development of new chemotherapy agents such as:

• Irinotecan
• Oxaliplatin
• Vascular endothelial growth factor receptor inhibitors (bevacizumab)
• Epidermal growth factor receptor inhibitors (cetuximab and panitumumab),
• Aflibercept
• Regorafenib: inhibitor of angiogenic tyrosine kinases (including the VEGF receptors 1,2, and 3),
• Capecitabine or 5-FU with or without a platinum drug

• Intraperitoneal chemotherapy including hyperthermic intraperitoneal chemotherapy plus/minus early postoperative intraperitoneal chemotherapy (EPIC)

• Introduction of Octereotide analogs to control symptmoes of carcinoid syndrome

• Development of new Imaging modalities

• CT scan, MRI as well as specific imaging modalities such as Somatostatin scintigraphy revolutionized approaching to the patients with appendix cancer

Future horizons

• Genetic studies revolutionized cancer treatment; appendix cancer is not an exception.
• Traditionally appandiceal cancers were approached the same as colorectal cancers. Recent genetic studies demonstrated that appendiceal tumors are clearly differ from colorectal cancers.
  • Presence of mutated TP53 and APC genes were significantly lower in appendiceal cancers compared to colorectal cancers.

• It has been shown that mutation profiles are associated with the patients’ prognosis.
  • Mutations in the TP53 significantly decrease life expectancy in patients with appendix cancer.
  • Regardless of tumor grade, Tp 53 mutations were associated with poorer outcomes.
  • Patients with GNAS mutations had a life expectancy of 10 years after diagnosis.
  • Appendiceal tumors with GNAS mutations rarely develop into high-grade tumors.

Famous Cases

The following are a few famous cases of appendix cancer:

• Celebrated actress, Audrey Hepburn was the most famous victims of appendix cancer, she passed away in 1993.

• Stuart Scott, ESPN sportscast anchor was diagnosed with appendix cancer in 2007 and died 8 years later in 2015.